Pseudoephedrine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00852 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 20 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | nasal cavity disease | KG + DL |
| 2 | acute laryngopharyngitis | KG + DL |
| 3 | allergic urticaria | KG + DL |
| 4 | trigeminal autonomic cephalalgia | KG + DL |
| 5 | rosacea conjunctivitis | KG + DL |
| 6 | cold urticaria | KG + DL |
| 7 | faucial diphtheria | KG + DL |
| 8 | cervical disc degenerative disorder | KG + DL |
| 9 | massive neonatal aspiration syndrome | KG + DL |
| 10 | bronchial disease | KG + DL |
| 11 | glossodynia | KG + DL |
| 12 | obsolete rare pulmonary disease | KG + DL |
| 13 | hantavirus infectious disease | KG + DL |
| 14 | coccygodynia | KG + DL |
| 15 | respiratory syncytial virus bronchiolitis | KG + DL |
| 16 | endobronchial leiomyoma | KG + DL |
| 17 | meconium aspiration syndrome | KG + DL |
| 18 | endobronchial lipoma | KG + DL |
| 19 | bronchus adenoma | KG + DL |
| 20 | lung disease | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.